Downregulation of LINC01857 Increases Sensitivity of Gastric Carcinoma Cells to Cisplatin

Background. The critical roles of long noncoding RNAs (lncRNAs) in the carcinogenesis and progression of cancers have been well documented. It was reported that lncRNAs were involved in chemotherapy resistance in various cancers. This study was aimed at clarifying the role of LINC01857 in cisplatin (DDP) resistance in gastric carcinoma (GC). Methods. The Cancer Genome Atlas (TCGA) database was used to analyze the expression of LINC01857 in GC tissues and normal tissues. The expression of LINC01857 in GC cells and DDP-resistant GC cells was detected by qRT-PCR. Cell viability and IC50 value were evaluated using the MTT assay. Moreover, cell apoptosis, migration, and invasion were determined using flow cytometry and Transwell assays, respectively. The expression of apoptosis-related proteins was examined by western blot. Results. TCGA database analysis revealed that LINC01857 expression was elevated in GC tissues compared with the normal tissues. qRT-PCR showed that the expression of LINC01857 was significantly higher in DDP-resistant cells than in GC and normal gastric cells. Knockdown of LINC01857 reduced cell viability in DDP-resistant cells. Moreover, LINC01857 downregulation promoted cell apoptosis and inhibited cell migration and invasion in DDP-resistant GC cells. Conclusions. LINC01857 was highly expressed in GC. Additionally, LINC01857 knockdown could facilitate the sensitivity to DDP and apoptosis and repressed cell migration and invasion in DDP-resistant GC cells, which provided a novel therapeutic target for chemotherapy resistance of GC in clinical practice.